Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30312068 | 1.00 | PARP1 (0.40) | PARP1PARP3NISCHMAOAMAOB | |
| SCHEMBL29802419 | 1.00 | PARP1 (0.40) | PARP1PARP3NISCHMAOAMAOB | |
| SCHEMBL14336651 | 0.84 | GAA (0.39) | PARP1KMT2ACYP19A1 | |
| SCHEMBL14336465 | 0.80 | PARP1 (0.34) | PARP1PARP3 | |
| SCHEMBL14336724 | 0.80 | PARP1 (0.33) | PARP1CDC7 | |
| SCHEMBL29960421 | 0.75 | HTR2A (0.55) | PARP1PARP3MAOACA12CA9 | |
| SCHEMBL7142349 | 0.75 | LMNA (0.39) | PARP1NISCHMAOAMAOBATM | |
| SCHEMBL14336530 | 0.74 | HTT (0.44) | MEN1LMNAKMT2A | |
| SCHEMBL14336466 | 0.72 | PHGDH (0.40) | PARP1LMNAMAPTKMT2A | |
| SCHEMBL7144469 | 0.72 | NISCH (0.40) | PARP1NISCHMAOAMAOBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282490-A2 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH Zürich (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11649268-B2 | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH ZURICH (CH) | 2023-05-16 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-20210393791-A1 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | HEALTH RESEARCH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-12 | — | — | US | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3325623-B3 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2021-01-20 | — | — | EP | disclosed |
| US-10874641-B2 | Methods of treating acute kidney injury | MITOBRIDGE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20050172365-A1 | Expression vector for improve exogenous gene transfer and transcription; transgenic organisms preferably plants which comprise these systems | SUNGENE GMBH & CO. KGAA (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1557414-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1531683-A2 | USE OF ASTAXANTHIN-CONTAINING PLANTS OR PARTS OF PLANTS OF THE GENUS TAGETES AS ANIMAL FEED | Sungene GmbH & Co. KGaA (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1407034-A2 | RECOMBINATION SYSTEMS AND A METHOD FOR REMOVING NUCLEIC ACID SEQUENCES FROM THE GENOME OF EUKARYOTIC ORGANISMS | Sungene GmbH & Co. KgAA (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| WO-2004017749-A2 | USE OF ASTAXANTHIN-CONTAINING PLANTS OR PARTS OF PLANTS OF THE GENUS TAGETES AS ANIMAL FEED | SUNGENE GMBH & CO. KGAA (DE) | 2004-03-04 | — | — | WO | disclosed |
| US-6514983-B1 | Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase | GUILFORD PHARMACEUTICALS INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2003004659-A2 | RECOMBINATION SYSTEMS AND A METHOD FOR REMOVING NUCLEIC ACID SEQUENCES FROM THE GENOME OF EUKARYOTIC ORGANISMS | SUNGENE GMBH & CO. KGAA (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874641-B2 | Methods of treating acute kidney injury | PARP1, PARP3, PARP11 | PARP1 1/4885PARP3 2/4885NISCH 4616/4885 |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | NQO1, PARP1, PARP11 | PARP1 2/4885PARP3 5/4885NISCH 1197/4885 |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885PARP3 1/4885NISCH 4878/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PARP1 2/4885PARP3 7/4885NISCH 2021/4885 |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885PARP3 15/4885NISCH 4609/4885 |
| US-20210393791-A1 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | PARP3, PARP1, PARP11 | PARP1 2/4885PARP3 1/4885NISCH 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.